Abstract: The present disclosure relates to pharmaceutical solid forms and pharmaceutical compositions comprising ibutamoren or a pharmaceutically acceptable salt thereof, and methods for administering to a pediatric subject for treating growth hormone deficiency.
Abstract: Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.
Type:
Grant
Filed:
May 22, 2020
Date of Patent:
November 1, 2022
Assignee:
LUMOS PHARMA, INC.
Inventors:
Mario Mautino, Sanjeev Kumar, Firoz Jaipuri, Jesse Waldo, Hima Potturi, Hong Zhuang
Abstract: Described herein is a new oral method for using MK-0677 for detecting growth hormone (GH) deficiency (GHD). Also described is a method of treating growth hormone (GH) deficiency (GHD) in children with a functional hypothalamic-pituitary GH axis.
Abstract: Described herein is a new oral method for using MK-0677 for detecting growth hormone (GH) deficiency (GHD). Also described is a method of treating growth hormone (GH) deficiency (GHD) in children with a functional hypothalamic-pituitary GH axis.
Abstract: Provided herein is a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, using cynamide in the reaction.
Type:
Grant
Filed:
September 1, 2015
Date of Patent:
December 3, 2019
Assignee:
Lumos Pharma, Inc.
Inventors:
William R. Cantrell, Jr., William E. Bauta
Abstract: Provided herein is a process and intermediates for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, using cyanamide in the reaction.
Type:
Grant
Filed:
August 21, 2018
Date of Patent:
August 13, 2019
Assignee:
Lumos Pharma, Inc.
Inventors:
William R. Cantrell, Jr., William E. Bauta
Abstract: Described herein is a new oral method for using MK-0677 for detecting growth hormone (GH) deficiency (GHD). Also described is a method of treating growth hormone (GH) deficiency (GHD) in children with a functional hypothalamic-pituitary GH axis.
Abstract: Provided herein is a process and intermediates for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, using cyanamide in the reaction.
Type:
Grant
Filed:
March 11, 2016
Date of Patent:
September 25, 2018
Assignee:
Lumos Pharma, Inc.
Inventors:
William R. Cantrell, Jr., William E. Bauta
Abstract: Provided herein is a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, using cynamide in the reaction.
Type:
Application
Filed:
September 1, 2015
Publication date:
September 28, 2017
Applicant:
Lumos Pharma, Inc.
Inventors:
William R. Cantrell, JR., William E. Bauta